Drugmakers Commit $500B to US Plants to Dodge Tariffs
Global drugmakers invest $500B in US to avoid tariffs, boosting domestic manufacturing. Learn how this impacts drug prices and supply chains.
This massive investment signals a significant shift in the pharmaceutical industry's manufacturing strategy, potentially leading to lower drug prices and increased supply chain resilience for American patients. It also underscores the economic impact of tariff policies, which are prompting companies to create jobs and bolster domestic production.
